Saturday, November 19, 2022 11:19:14 AM
LC, nice to hear from you!
There is some truth in everything you say but in 25 years I've never had a perfect investment. It's always comes down to judgement and then being mentally flexible as the information develops. On the most important information -- the trial data and how that data would be received by the medical community -- is clearly favorable.
The stock lost ground recently as the markets went from speculative to risk adverse. If we were still in a bull market, the stock would be 3+.
Some things, like the board stuff, need work. The presence of institutional investors fixes that and, historically, it hasn't been in my interest to address it.
TTFs aren't used widely enough to cause an approval issue, in my view. Experimental treatments are experimental.
So, why don't you tell me about your perfect investment? I would love one of those :)
There is some truth in everything you say but in 25 years I've never had a perfect investment. It's always comes down to judgement and then being mentally flexible as the information develops. On the most important information -- the trial data and how that data would be received by the medical community -- is clearly favorable.
The stock lost ground recently as the markets went from speculative to risk adverse. If we were still in a bull market, the stock would be 3+.
Some things, like the board stuff, need work. The presence of institutional investors fixes that and, historically, it hasn't been in my interest to address it.
TTFs aren't used widely enough to cause an approval issue, in my view. Experimental treatments are experimental.
So, why don't you tell me about your perfect investment? I would love one of those :)
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
